Expression of epstein-barr virus-encoded proteins in extranodal NK/T-cell lymphoma, nasal type (ENKL): Differences in biologic and clinical behaviors of LMP1-positive and -negative ENKL

Clinical Cancer Research

Volumn 18, Issue 8, 2012, Pages 2164-2172

  Kanemitsu, Naoko ^a   Isobe, Yasushi ^a   Masuda, Azuchi ^a   Momose, Shuji ^a   Higashi, Morihiro ^b   Tamaru, Jun Ichi ^b   Sugimoto, Koichi ^a   Komatsu, Norio ^a  

^a JUNTENDO UNIVERSITY   (Japan)

^b SAITAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

LATENT MEMBRANE PROTEIN 1; LATENT MEMBRANE PROTEIN 2; LATENT MEMBRANE PROTEIN 2A; PROTEIN KINASE B; TRANSCRIPTION FACTOR RELA; UNCLASSIFIED DRUG; VIRUS RNA;

AGED; ARTICLE; CANCER PROGNOSIS; CELL STRUCTURE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME PHOSPHORYLATION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; MALE; NATURAL KILLER CELL; NK T CELL LYMPHOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; SURVIVAL RATE; VIRUS CARCINOGENESIS;

ADULT; AGED; CELL LINE, TUMOR; EPSTEIN-BARR VIRUS INFECTIONS; EPSTEIN-BARR VIRUS NUCLEAR ANTIGENS; FEMALE; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHOMA, EXTRANODAL NK-T-CELL; MALE; MIDDLE AGED; PROTO-ONCOGENE PROTEINS C-AKT; RIBOSOMAL PROTEINS; RNA INTERFERENCE; RNA, SMALL INTERFERING; RNA-BINDING PROTEINS; TRANSCRIPTION FACTOR RELA; VIRAL MATRIX PROTEINS; VIRAL PROTEINS;

EID: 84859826619     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-2395     Document Type: Article

References (40)

1. Chan JKC, Quintanilla-Martinez L, Ferry JA, Peh SC. Extranodal NK/T-cell lymphoma, nasal type. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al., editors. World Health Organization classification of tumors of haematopoietic and lymphoid tissues. Lyon, France: IARC Press; 2008. p. 285-8.
2. International T-cell Lymphoma Project. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol 2008;26:4124-30.
3. Lee J, Suh C, Park YH, Ko YH, Bang SM, Lee JH, et al. Extranodal natural killer T-cell lymphoma, nasal-type: a prognostic model from a retrospective multicenter study. J Clin Oncol 2006;24:612-8. (Pubitemid 46630424)
4. Suzuki R, Suzumiya J, Yamaguchi M, Nakamura S, Kameoka J, Kojima H, et al. Prognostic factors for mature natural killer (NK) cell neoplasms: aggressive NK cell leukemia and extranodal NK cell lymphoma, nasal type. Ann Oncol 2010;21:1032-40.
5. Yamaguchi M, Tobinai K, Oguchi M, Ishizuka N, Kobayashi Y, Isobe Y, et al. Phase I/II study of concurrent chemoradiotherapy for localized nasal natural killer/T-cell lymphoma: Japan Clinical Oncology Group Study JCOG0211. J Clin Oncol 2009;27:5594-600.
6. Kim SJ, Kim K, Kim BS, Kim CY, Suh C, Huh J, et al. Phase II trial of concurrent radiation and weekly cisplatin followed by VIPD chemotherapy in newly diagnosed, stage IE to IIE, nasal, extranodal NK/T-cell lymphoma: Consortium for Improving Survival of Lymphoma Study. J Clin Oncol 2009;27:6027-32.
7. Oshimi K. Progress in understanding and managing natural killer-cell malignancies. Br J Haematol 2007;139:532-44. (Pubitemid 350043813)
8. Au WY, Weisenburger DD, Intragumtornchai T, Nakamura S, Kim WS, Sng I, et al. Clinical differences between nasal and extranasal natural killer/T-cell lymphoma: a study of 136 cases from the International Peripheral T-Cell Lymphoma Project. Blood 2009;113:3931-7.
9. Rickinson AB, Kieff E. Epstein-Barr virus. In: Knipe DM, Howley PM, et al., editors. Fields virology. 5th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2007. p. 2655-700.
10. Kieff ED, Rickinson AB. Epstein-Barr virus and its replication. In: Knipe DM, Howley PM, et al., editors. Fields virology. 5th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2007. p. 2603-54.
11. Young LS, Rickinson AB. Epstein-Barr virus: 40 years on. Nat Rev Cancer 2004;4:757-68. (Pubitemid 39331148)
12. Isobe Y, Sugimoto K, Yang L, Tamayose K, Egashira M, Kaneko T, et al.: Epstein-Barr virus infection of human natural killer cell lines and peripheral blood natural killer cells. Cancer Res 2004;64:2167-74. (Pubitemid 38339469)
13. Yoshiyama H, Shimizu N, Takada K. Persistent Epstein-Barr virus infection in a human T-cell line: unique program of latent virus expression. EMBO J 1995;14:3706-11.
14. Hislop AD, Taylor GS, Sauce D, Rickinson AB. Cellular responses to viral infection in humans: lessons from Epstein-Barr virus. Annu Rev Immunol 2007;25:587-617. (Pubitemid 46697918)
15. Chiang AK, Tao Q, Srivastava G, Ho FC. Nasal NK- and T-cell lymphomas share the same type of Epstein-Barr virus latency as nasopharyngeal carcinoma and Hodgkin's disease. Int J Cancer 1996;68:285-90. (Pubitemid 26384128)
16. Xu ZG, Iwatsuki K, Oyama N, Ohtsuka M, Satoh M, Kikuchi S, et al. The latency pattern of Epstein-Barr virus infection and viral IL-10 expression in cutaneous natural killer/T-cell lymphomas. Br J Cancer 2001;84:920-5. (Pubitemid 32385835)
17. Isobe Y, Aritaka N, Sasaki M, Oshimi K, Sugimoto K. Spontaneous regression of natural killer cell lymphoma. J Clin Pathol 2009;62:647-50.
18. Ando J, Sugimoto K, Ando M, Isobe Y, Sasaki M, Oshimi K. CD20-positive extranodal NK-cell lymphoma, nasal type. Eur J Haematol 2008;80:549-50. (Pubitemid 351677460)
19. Tsuchiyama J, Yoshino T, Mori M, Kondoh E, Oka T, Akagi T, et al. Characterization of novel human natural killer-cell line (NK-YS) establishment from natural killer cell lymphoma/leukemia associated with Epstein-Barr virus infection. Blood 1998;92:1374-83. (Pubitemid 28369051)
20. + phenotype and associated with the Epstein-Barr virus. Br J Haematol 1998;103:669-77.
21. Robertson MJ, Cochran KJ, Cameron C, Le JM, Tantravahi R, Ritz J. Characterization of a cell line, NKL, derived from aggressive human natural killer cell leukemia. Exp Hematol 1996;24:406-15. (Pubitemid 26098857)
22. Iwata S, Wada K, Tobita S, Gotoh K, Ito Y, Demachi-Okamura A, et al. Quantitative analysis of Epstein-Barr virus (EBV)-related gene expression in patients with chronic active EBV infection. J Gen Virol 2010;91:42-50.
23. Bell AI, Groves K, Kelly GL, Croom-Carter D, Hui E, Chan ATC, et al. Analysis of Epstein-Barr virus latent gene expression in endemic Burkitt's lymphoma and nasopharyngeal carcinoma tumor cells by using quantitative real-time PCR assays. J Gen Virol 2006;87:2885-90. (Pubitemid 44463896)
24. Fox CP, Haigh TA, Taylor GS, Long HM, Lee SP, Shannon-Lowe C, et al. A novel latent membrane 2 transcript expressed in Epstein-Barr virus-positive NK- and T-cell lymphoproliferative disease encodes a target for cellular immunotherapy. Blood 2010;116:3695-704.
25. Kis LL, Takahara M, Nagy N, Klein G, Klein E. IL-10 can induce the expression of EBV-encoded latent membrane protein-1 (LMP-1) in the absence of EBNA-2 in B lymphocytes and Burkitt lymphoma- and NK lymphoma- derived cell lines. Blood 2006;107:2928-35.
26. Boulland M-L, Meignin V, Leroy-Viard K, Copie-Bergman C, Briere J, Touitou R, et al. Human interleukin-10 expression in T/natural killer-cell lymphomas. Am J Pathol 1998;153:1229-37.
27. Teruya-Feldstein J, Jaffe ES, Burd PR, Kanegane H, Kingma DW, Wilson WH, et al. The role of Mig, the monokine induced by interferon-γ, and IP-10, the interferon-γ-inducible protein-10, in tissue necrosis and vascular damage associated with Epstein-Barr virus-positive lymphoproliferative disease. Blood 1997;90:4099-105. (Pubitemid 27484065)
28. Shen L, Chiang AKS, Liu WP, Liang RHS, Srivastava G. Expression of HLA class I, β2-microglobulin, Tap1 and IL-10 in Epstein-Barr virus-associated nasal NK/T-cell lymphoma: implications for tumor immune escape mechanism. Int J Cancer 2001;92:692-6. (Pubitemid 32385712)
29. Chow C, Liu AY, Chan WS, Lei KIK, Chan WY, Lo AWI. Akt plays a role in the survival of the tumor cells of extranodal NK/T-cell lymphoma, nasal type. Haematologica 2005;90:274-5. (Pubitemid 40293300)
30. Chan K-K, Shen L, Au W-Y, Yuen H-F, Wong K-Y, Guo T, et al. Interleukin-2 induces NF-κB activation through BCL10 and affects its subcellular localization in natural killer lymphoma cells. J Pathol 2010;221:164-74.
31. Cherney BW, Sgadari C, Kanegane C, Wang F, Tosato G. Expression of the Epstein-Barr virus protein LMP1 mediates tumor regression in vivo. Blood 1998;91:2491-500. (Pubitemid 28155525)
32. Gottschalk S, Edwards OL, Sili U, Huls MH, Goltsova T, Davis AR, et al. Generating CTLs against the subdominant Epstein-Barr virus LMP1 antigen for the adoptive immunotherapy of EBV-associated malignancies. Blood 2003;101:1905-12. (Pubitemid 36237592)
33. Mehl AM, Floettmann JE, Jones M, Brennan P, Rowe M. Characterization of intercellular adhesion molecule-1 regulation by Epstein-Barr virus-encoded latent membrane protein-1 identifies pathways that cooperate with nuclear factor κB to activate transcription. J Biol Chem 2001;276:984-92. (Pubitemid 32096518)
34. Peng M, Lundgren E. Transient expression of the Epstein-Barr virus LMP1 gene in B-cell chronic lymphocytic leukemia cells, T cells, and hematopoietic cell lines: cell-type-independent-induction of CD23, CD21, and ICAM-1. Leukemia 1993;7:104-12. (Pubitemid 23048928)
35. Demachi-Okamura A, Ito Y, Akatsuka Y, Tsujimura K, Morishima Y, Takahashi T, et al. Epstein-Barr virus (EBV) latent membrane protein-1-specific cytotoxic T lymphocytes targeting EBV-carrying natural killer cell malignancies. Eur J Immunol 2006;36:593-602.
36. Kobayashi H, Nagato T, Takahara M, Sato K, Kimura S, Aoki N, et al. Induction of EBV-latent membrane protein 1-specific MHC class II-restricted T-cell responses against natural killer lymphoma cells. Cancer Res 2008;68:901-8. (Pubitemid 351206769)
37. Diepstra A, van Imhoff GW, Schaapveld M, Karim-Kos H, van den Berg A, Vellenga E, et al. Latent Epstein-Barr virus infection of tumor cells in classical Hodgkin's lymphoma predicts adverse outcome in older adult patients. J Clin Oncol 2009;27:3815-21.
38. Claviez A, Tiemann M, Lüders H, Krams M, Parwaresch R, Schellong G, et al. Impact of latent Epstein-Barr virus infection on outcome in children and adolescents with Hodgkin's lymphoma. J Clin Oncol 2005;23:4048-56. (Pubitemid 46211309)
39. Hu L-F, Chen F, Zhen Q-F, Zhang Y-W, Luo Y, Zheng X, et al. Differences in the growth pattern and clinical course of EBV-LMP1 expressing and non-expressing nasopharyngeal carcinomas. Eur J Cancer 1995;31:658-60.
40. Khabir A, Karray H, Rodriguez S, Rosé M, Daoud J, Frikha M, et al. EBV latent membrane protein I abundance correlates with patient age but not with metastatic behavior in north African nasopharyngeal carcinomas. Virol J 2005;2:39.